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Summary The accuracy of cancer registration data in the East of Scotland (Tayside) Cancer Registry was
audited by comparing 200 consecutive registrations (about 10% of the annual total) with the 'gold standard'
of the Histopathology records. ICD codes were independently generated by a pathologist by examining final
pathology reports and then compared to those codes given by the local cancer registrar. Discrepancies were
graded by the pathologist and the epidemiologist according to severity. Major errors of coding were few.
Minor and moderate differences in coding occurred because of the nature and structure of the coding system
and the manner in which data are retrieved. The level of detail required by the Cancer Registry needs to be
evaluated.
Population-based cancer registry data are used to monitor
incidence of, and survival from, the many types of cancer.
Geographical differences in incidence stimulate thoughts
about, and research into, the causes of cancer. However
because some cancers are quite rare, the data must be highly
accurate. A few cases misclassified could lead to apparently
large differences in rates.
The Scottish Cancer Registration scheme had its origins in
a system set up in 1936 by the National Radium Commis-
sion, and has developed over the years (S.H.H.D., 1990).
Five regional registries feed information to the national one,
based in the Information and Statistics Division of the Com-
mon Services Agency of the Scottish Health Service. The
data can be used not only for monitoring incidence and
survival, but by Health Boards assessing health care needs,
evaluating the success of treatment, for economic appraisal
of services, for assessing the representativeness of patients
enrolled into clinical trials, for health education, where local
information may have more impact than national rates, for
record linkage to study the incidence of cancer in cohorts
exposed to a possible carcinogen, and for assessing the
effectiveness of cervical and breast screening programmes.
Registration data have advantages over cancer mortality
rates since survival rates can be calculated, and as the inter-
val between exposure to a cause or causes, and incidence is
less than that between exposure and mortality, retrospective
enquiry should be easier.
Sources of information include Pathology and
Haematology Departments, Radiotherapy Units, records
staff in hospitals (through the cancer notification form, or
from discharge summaries), General Register Office (by list-
ing of deaths where cancer is mentioned), and various ad hoc
sources, such as local specialist registers, screening program-
mes and research projects (S.H.H.D., 1990). The duplication
of data from different sources helps ensure completeness of
ascertainment, and the quality of data is thought to be very
good.
However, one of the principles of audit suggested at the
first meeting of the Tayside Medical Audit Committee, was
that it was important to audit activities which were thought
to be done well - nothing should be taken too much for
granted.
The aim of this project was to examine the accuracy of
registry data, by comparison with the 'gold standard' of
Pathology reports, and with clinical case notes when
required.
The East of Scotland registry records around 2,200 new
cancers per annum. It is not at present computerised, and has
three files, one by patient in alphabetical order, one by
tumour, and one in registration order. Computerisation is
eagerly awaited, and should happen late in 1991.
Method
The names and Community Health Index numbers of 200
patients consecutively registered with the Tayside Regional
Cancer Registry in early 1988, were extracted by the audit
assistant. Pathology reports for these patients were then
examined (if available) by the pathologist (RL) and the
correct ICD 9 code for each cancer decided. Where there was
no Pathology report (RL) examined the Hospital notes and
decided the appropriate ICD 9 (WHO, 1977) classification.
These clinician verified classifications were then compared
with the codes allocated by the Cancer Registrar to identify
cases where the codes differed. Discrepancies were classified
in three grades:
Minor where there were differences in precise localisation.
Moderate where there was a misclassification of particular
category of neoplasm within the main classification; some-
times such errors arose because of the archaic terminology of
the ICD 9 code (e.g. continued use of terms 'lymphosarcoma'
and 'reticulosarcoma').
Serious where a major misdiagnosis was given by Cancer
Registry such as omission of second primary or allocation to
an incorrect region (e.g. appendix adenocarcinoma attributed
to rectum).
The reasons for the discrepancies were then examined. The
Director of Cancer Registry then considered whether the
differences would have significant effects on the epidemio-
logical functions of cancer registration, and reclassified dis-
crepancies accordingly.
Results
The pathologist (RL) had access to histopathology surgical
reports and post mortem reports that were carried out by the
Department of Pathology Ninewells flospital. This included
surgical specimens received and post mortems of patients
from Tayside Health Board including Ninewells Hospital,
Dundee Royal Infirmary, Stracathro Hospital and Royal
Victoria Hospital.
The surgical reports and post mortem reports were
examined for details of site of tumour and type of tumour as
required for ICD coding. Out of the 200 cases, 186 of the
cases had corresponding pathology reports. In 11 of the cases
hospital notes were required to confirm site and type of
tumour. In three cases neither hospital notes nor pathology
reports were available.
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The ICD codes allocated by the reviewing pathologist (RL)
were then compared with those given by the Cancer Regis-
trar.
Of the cases examined, 145 were assigned the same ICD
code by (RL) and the Cancer Registrar. Of these, 137 were
confirmed by Pathology reports, eight were confirmed by
Hospital notes.
The other 52 cases were assigned different ICD codes by
(RL) and the Cancer Registrar of which (RL) sited 35 cases
with minor differences, 6 with moderate differences and 11
with serious differences.
Of the minor differences, 29 cases were given different ICD
codes due to minor differences in site of tumour (Tables I
and II). Although the organ site was correct, the location
within the organ differed (e.g. lung vs upper lobe, middle
lobe, lower lobe). These differences sometimes occurred
because more detailed information was available to (RL)
from the Pathology report (e.g. Pathology reports gave gross
descriptions of large surgical specimens or detailed localisa-
tion of tumours in necropsies which were not ascertained by
the Cancer Registrar). However in other cases the Cancer
Registry received more clinical information and so was more
reliable or in other cases it relied on registration from con-
current cytology reports. In this Audit more information and
therefore more accurate ICD codes were given by (RL) in 19
cases and by the Cancer Registrar in 9 cases. Six other minor
discrepancies were also found, but these probably occurred
because additional information was subsequently made
available to the Cancer Registrar (Table III). Moderate
differences in ICD coding were found in six cases. Four of
these were differences in classification of Lymphoma. One
Well Differentiated Lymphocytic Lymphoma was registered
as Lymphosarcoma by the Cancer Registrar, and one Diffuse
High Grade Immunoblastic Lymphoma was registered as a
Reticulosarcoma. Two Nodular Sclerosing Hodgkin's Disease
were registered as Unspecified Hodgkin's Disease. This type
Table I Minor differences
Number of cases with different codes
Site assigned by (RL) and Cancer Registrar
Lung or bronchus 9
Colon 9
Stomach 4
Female breast 3
Kidney I
Larynx I
Brain I
Skin I
Table II Minor differences
RL Cancer Registrar
Main bronchus (2 cases) Bronchus and lung, unspecified
Upperlobe(2cases) Bronchusand lung, unspecified
Bronchus and lung unspecified Main bronchus (3 cases)
Bronchus and lungunspecified Upper lobe
Bronchusand lungunspecified Lower lobe
Transverse colon Abdomen
Transversecolon Colon, unspecified
Sigmoidcolon Colon, unspecified
Caecum (3 cases) Colon, unspecified
Ascendingcolon Colon, unspecified
Ascendingcolon Caecum
Other, colon Colon, unspecified
Cardia Stomach, unspecified
Lessercurvature, unspecified Stomach, unspecified
Other, stomach Stomach, unspecified
Breast, unspecified Upper inner quadrant breast
Breast, unspecified Lower innerquadrant breast
Other, breast Breast, unspecified
Renal pelvis Kidney, except pelvis
Glottis Larynx, unspecified
Brain, unspecified Cerebellum
Skin oftrunk Skin oflower limb
Table HI Minor differences (not true errors)
RL Cancer Registrar
Omentum secondary neoplasm Gastro-oesophageal primary
Pleura and liver secondary Lung primary
Submandibular lymph node Pharynx primary
secondary
Omentum secondary Stomach primary
Tonsil secondary Floor of mouth primary
Skin secondary Kidney primary
of discrepancy is a direct result of ICD lagging behind cur-
rent medical practice terminology.
Two of the moderate differences relate to site. The
Pathology report was not clear as to the type of tumour
however the Cancer Registrar had given a definitive site ICD
code. The category for carcinoma unspecified site was not
used in these two cases (e.g. (RL) -bronchus? large cell
neoplastic or renal metastasis, Cancer Registrar -bronchus
carcinoma; (RL) -liver moderately differentiated adenocar-
cinoma? metastasis or 10 cholangiocarcinoma, Cancer Regist-
rar -liver secondary carcinoma).
Eleven differences considered serious by the Pathologist
were found. One of these was a case in which (RL) felt there
were two different neoplasms requiring separate ICD codes
but only one was given by the Cancer Registrar. (e.g. (RL)
-Prostate Adenocarcinoma and Prostatic Urethra Transi-
tional Cell Carcinoma; Cancer Registrar -Prostatic
Adenocarcinoma only).
One case differed in coding due to Behaviour of tumour as
(RL) felt Ovary Borderline Mucinous Cystadenocarcinoma
should be registered under Neoplasm of Uncertain
Behaviour.
Eight of the serious differences occurred because of
spurious differences in site (Table IV).
In one case neither Pathology reports or Hospital notes
showed any evidence of a neoplasm, but the Cancer Regist-
rar gave an ICD code for Carcinoma of Unspecified type
(Carcinomatosis).
Epidemiological review showed that of the 35 minor
differences, only the nine cases with differences of site within
colon (e.g. caecum versus colon unspecified) are of possible
significance, since it may be that the aetiology of cancer of
one part of the colon differs from that of another.
Of the moderate differences (six), the four lymphoma cases
may matter, since such tumours are not common. In Tayside,
the average numbers of cases per annum are:-
Hodgkin's - 10
Other lymphoid and histiocytic tissue- 28
Lymphosarcoma and reticulosarcoma - 20
It was felt therefore that a few misclassified cases could
affect apparent incidence, and that this was an area of con-
cern.
Table IV Serious differences
RL Cancer Registrar
Appendix primary Rectum adenocarcinoma
adenocarcinoma
Omentum secondary carcinoma Omentum primary carcinoma
Skin (L) ear, (R) cheek Skin (R) ear, (R) carcinoma
squamous carcinoma cheek (I ICD code)
(2 ICD codes)
Liver secondary carcinoma Liver primary carcinoma
Maxilla primary carcinoma Antrum (stomach) primary
carcinoma
Prostate - carcinoma arising Prostatic carcinoma
urethra epithelium
Pancreas ? Metastasis Pancreas primary
Jaundice ? Pancreatic Pancreas primary
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The serious differences (11) were composed mainly of two
categories, firstly secondaries classed as primaries, and
secondly wrong sites. The latter were too few to affect
incidence rates, and hence are not of epidemiological
significance. The former could be significant in cases such as
liver, where primary tumours are uncommon (usually around
15 per annum in Tayside). Hence two cases respectively
misclassified could increase reported incidence by 13%.
Discussion
Fifty two out of 200 cases with different codes represents a
fair proportion of differences between (RL) and the Cancer
Registrar. At most eight of these (4% of total) represent
serious differences in which a site was coded wrongly. Prob-
lems inherent in the structure of the audit account for a few
of the minor differences in ICD codes as (RL) was restricted
to pathology reports and examined hospital notes only in
cases when pathology notes were not available.
Numerically the large bulk of minor differences (29) and
moderate differences have occurred because of the nature of
the ICD coding and the manner in which data is retrieved.
The pathology reports are an easy and reliable way to obtain
data for registration purposes and as this study shows 186
out of 200 cases examined had pathology reports. They have
reliable data as to tumour type. The site however, in certain
cases, tends to be less well defined. In biopsy specimens this
data is supplied on the request form by the clinician and is
usually not as detailed as the ICD coding requires (e.g. exact
site on lip - upper lip vermilion border, lower lip vermilion
border, upper lip inner aspect, lower lip inner aspect, lip
unspecified inner aspect, commissure of lip, other, lip uns-
pecified vermilion border). The exact site is often not neces-
sary to the pathologist in making his disease category diag-
nosis. If an entire specimen is received the detailed inform-
ation as to site within an organ may be in the pathology
report gross description but this may not be easily inferred
by secretarial staff transferring information to be registered.
Perhaps a more simplified coding to site should be considered
as the current method of coding results in data with many
inaccuracies in detailed site within an organ, and certainly an
abundance of ICD codes given with an unspecified site within
an organ. Otherwise more time consuming and laborious
consultation of hospital notes and canvassing of clinical data
would be required for more accurate coding. If computerisa-
tion of cancer registration places more reliance on pathology
reports spurious inaccuracies will be created by lack of exact
sites being quoted on request forms. The Cancer Registrar's
access to a range of other data sources can improve data
quality.
Another main category that contains inadequacies in its
format are those codes concerning primary neoplasms of
lymphatic and haematopoietic tissue. This includes sections
'Lymphosarcoma and Reticulosarcoma, Hodgkin's disease,
and other malignant neoplasms of lymphoid and histiocytic
tissue'. The classification of lymphomas and lymphop-
roliferative disorders is a vast and specialised field. The ICD
coding system makes attempts at categorising some of these
neoplasms and disorders. The Cancer Registrars receive some
training in assigning ICD codes but in such a rapidly chang-
ing and complicated subject it is optimistic to suggest a
structured coding for lymphomas in this setting. This audit
revealed two cases of lymphoma that were categorised under
Reticulosarcoma and Lymphosarcoma. This terminology is
now outdated and their meaning is obscure in light of more
advanced terminology. The Hodgkin's diseases are coded by
two subclassifications, the Parker Jackson classification and
the Rye modification of Lukes-Butler. The Parker Jackson
classification dates from 1947 and again is outdated and
redundant terminology that should be discarded. The Rye
modification of Lukes-Butler is presently a good standard
classification but as this audit showed two cases of Nodular
Sclerosing Hodgkin's disease were classified as Unspecified
Hodgkin's disease (Robb-Smith & Taylor 1981).
Other similar difficulties are present in the categories of
'other malignant neoplasms of lymphoid and histiocytic tis-
sue'. These problems highlight again that errors are produced
by complicated categories.
This audit shows that major errors of coding are few,
however there are numerous differences in coding between
the auditor and the Cancer Registrar that occurred because
of the structure and age of the ICD classification, and the
way information is obtained. The Cancer Registry needs to
consider the level of detail required. If exact sites are neces-
sary then more meticulous collection of clinical data will be
required to avoid unspecified or wrong sites being quoted. If
automatic download of information from the histopathology
computer system becomes the main source of cancer registry
data, it wilil need to be supplemented from other sources
unless clinicians can be persuaded to improve on request
forms.
The problems of outdated ICD classification are more
difficult to overcome. This audit was carried out towards the
end of the life of ICD 9. It is probably unrealistic to expect
any classification which can be revised only every 10-15
years to keep pace with advances in medical science, and
since the implementation of each revision creates con-
siderable problems for records staff, statisticians and epide-
miologists, more frequent revision would not be welcome.
For many purposes, summarised cancer registration data
are adequate, and the discrepancies noted here are not
important. It is probably only when a rare tumour is being
studied, that they are of epidemiological significance. For
example, at present there is considerable interest in incidence
of lymphomas and leukaemias in areas close to nuclear ins-
tallations. However in such studies (Heasman et al., 1987;
Roman et al., 1987) it is usual for diagnosis to be verified
from both clinical and pathological records. It would be wise
for this to continue.
In conclusion, the quality of cancer registration data is
good, but could be improved. Since we completed this study,
the Scottish Cancer Registration Organisation has held a
study day for cancer registrars and others, on the topic of
classification and registration of lymphomas and leukaemias.
Further improvements should follow computerisation of the
registry, which will permit much greater use of the data,
including feedback to clinicians, who will be encouraged to
comment on possible inaccuracies. Computerisation
elsewhere - for example in Radiotherapy, Haematology and
Gynaecology - will also help by providing lists of patients
with specific cancers, which can be used to check com-
pleteness of registry ascertainment.
We thank Mrs M. Cannon, Cancer Registrar, and Mrs G. Alex-
ander, Medical Audit Assistant for extracting registrations, and Pro-
fessor J. Swanson Beck for commenting on the first draft.
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